Protalix BioTherapeutics Inc announced positive interim results from the Company’s phase II clinical trial of alidornase alfa for the treatment of Cystic Fibrosis (CF) for the first 13 CF patients enrolled in the study.
GENFIT a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced that the FDA has cleared the IND to proceed with the Phase II trial aimed at evaluating elafibranor in PBC.
SYNCONA LLP and CANCER RESEARCH TECHNOLOGY (CRT) announce the formation of Achilles Therapeutics Ltd .The new private company will bring together world-class research from UCL (University College London) and the Francis Crick Institute, funded by Cancer Research UK and the National Institute for Health Research (NIHR).
Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, and OSE Immunotherapeutics SA announced the signing of two service agreements that provide OSE Immunotherapeutics with access to high performance research cell banks (RCBs) from the Selexis SUREtechnology Platform™.
Spark Therapeutics and Pfizer Inc announced that Lindsey A. George, M.D a hematologist and attending physician at the Children’s Hospital of Philadelphia and lead investigator in the Phase 1/2 clinical trial of SPK-9001 for treatment of hemophilia B, will present an updated dataset from the ongoing Phase 1/2 clinical trial of SPK-9001 at the 58th American Society of Hematology (ASH) Annual Meeting, to be held Dec. 3-6, 2016, in San Diego.